- Home
- SGLY vs INDP Comparison
SGLY vs INDP Comparison
Compare SGLY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | INDP |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.7M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGLY | INDP |
|---|---|---|
| Price | $0.37 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 183.7K | 55.4K |
| Earning Date | 02-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,619,679.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $1.52 |
| 52 Week High | $1.86 | $47.60 |
Technical Indicators
Market Signals| Indicator | SGLY | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 29.54 | 35.00 |
| Support Level | $0.53 | $2.60 |
| Resistance Level | $0.45 | $2.66 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 19.34 | 12.74 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.